Llwytho...
Pembrolizumab‐induced interstitial lung disease following thoracic surgery in a patient with non‐small cell lung cancer
The safety of treatment with immune‐checkpoint inhibitors prior to thoracic surgery in patients with non‐small cell lung cancer (NSCLC) remains unclear. Here, we describe the case of a 62‐year‐old woman with NSCLC with programmed death ligand 1 expression on 85% of tumor cells. The patient was initi...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Thorac Cancer |
|---|---|
| Prif Awduron: | , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley & Sons Australia, Ltd
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6825914/ https://ncbi.nlm.nih.gov/pubmed/31512401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13194 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|